Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders

被引：42

作者：

Kayed, Rakez ^{[1
]}

Jackson, George R. ^{[1
]}

机构：

[1] Univ Texas Med Branch, George P & Cynthia Woods Mitchell Ctr Neurodegene, Galveston, TX 77555 USA

来源：

CURRENT OPINION IN IMMUNOLOGY | 2009年 / 21卷 / 03期

关键词：

AMYLOID-BETA PEPTIDE; A-BETA; MOUSE MODEL; NEURODEGENERATIVE DISEASES; TRANSGENIC MICE; NEUROFIBRILLARY TANGLES; ANIMAL-MODELS; IMMUNIZATION; PROTEIN; PATHOLOGY;

D O I：

10.1016/j.coi.2009.05.001

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Alzheimer disease (AD) is the most common neurodegenerative disorder. Currently available therapies may slow cognitive decline but do not alter underlying disease processes. Considerable effort over the last decade has been directed toward the development of vaccines for AD; these have been primarily directed against the A beta peptide, a component of senile plaques. More recently, alternative approaches have begun to target the microtubule binding protein tau, a component of neurofibrillary tangles. Immunotherapies based upon oligomeric species of tau represent a promising new approach for AD.

引用

页码：359 / 363

页数：5

共 76 条

[1] The development of anti-amyloid therapy for Alzheimer's disease - From secretase modulators to polymerisation inhibitors [J].

Aisen, PS .

CNS DRUGS, 2005, 19 (12) :989-996

[2] Alzheimer's disease:: the pharmacological pathway [J].

Allain, H ;

Bentué-Ferrer, D ;

Tribut, O ;

Gauthier, S ;

Michel, BF ;

Drieu-La Rochelle, C .

FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2003, 17 (04) :419-428

[3] Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms [J].

Andorfer, C ;

Acker, CM ;

Kress, Y ;

Hof, PR ;

Duff, K ;

Davies, P .

JOURNAL OF NEUROSCIENCE, 2005, 25 (22) :5446-5454

[4] A tale about tau [J].

Ashe, Karen H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (09) :933-935

[5] Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements [J].

Asuni, Ayodeji A. ;

Boutajangout, Allal ;

Quartermain, David ;

Sigurdsson, Einar M. .

JOURNAL OF NEUROSCIENCE, 2007, 27 (34) :9115-9129

[6] Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease [J].

Augustinack, JC ;

Schneider, A ;

Mandelkow, EM ;

Hyman, BT .

ACTA NEUROPATHOLOGICA, 2002, 103 (01) :26-35

[7] Tau-mediated neurodegeneration in Alzheimer's disease and related disorders [J].

Ballatore, Carlo ;

Lee, Virginia M. -Y. ;

Trojanowski, John Q. .

NATURE REVIEWS NEUROSCIENCE, 2007, 8 (09) :663-672

[8] Early Tau Pathology Involving the Septo-Hippocampal Pathway in a Tau Transgenic Model: Relevance to Alzheimer's Disease [J].

Belarbi, Karim ;

Schindowski, Katharina ;

Burnouf, Sylvie ;

Caillierez, Raphaelle ;

Grosjean, Marie-Eve ;

Demeyer, Dominique ;

Hamdane, Malika ;

Sergeant, Nicolas ;

Blum, David ;

Buee, Luc .

CURRENT ALZHEIMER RESEARCH, 2009, 6 (02) :152-157

[9] Accumulation of pathological tau species and memory loss in a conditional model of tauopathy [J].

Berger, Zdenek ;

Roder, Hanno ;

Hanna, Amanda ;

Carlson, Aaron ;

Rangachari, Vijayaraghavan ;

Yue, Mei ;

Wszolek, Zbigniew ;

Ashe, Karen ;

Knight, Joshua ;

Dickson, Dennis ;

Andorfer, Cathy ;

Rosenberry, Terrone L. ;

Lewis, Jada ;

Hutton, Mike ;

Janus, Christopher .

JOURNAL OF NEUROSCIENCE, 2007, 27 (14) :3650-3662

[10] Consequence of A immunization on the vasculature of human Alzheimers disease brain [J].

Boche, D. ;

Zotova, E. ;

Weller, R. O. ;

Love, S. ;

Neal, J. W. ;

Pickering, R. M. ;

Wilkinson, D. ;

Holmes, C. ;

Nicoll, J. A. R. .

BRAIN, 2008, 131 :3299-3310

← 1 2 3 4 5 6 7 8 →